Episode 105: In the Clinic - the ADePT Trial in Glioblastoma - dual payload gene therapy - with Dr Faye Robertson

Send us Fan Mail (buzzsprout.com/2342317/fan_mail/new)
Sometimes we hear about a vision for a trial that is so novel and exciting that it takes you back a bit.
This is one such moment.
Join us as we talk to the amazing Dr Faye Robertson from the Edinburgh cancer Centre about the ingenious ADePT trial.

DUAL PAYLOAD GENE THERAPY.
Led by Trogenix and the University of Edinburgh, it tests a breakthrough "Trojan horse" gene therapy designed to destroy cancer cells and stimulate the immune system.
TGX-007 is a drug developed with Tregonix that:
How it Works: It uses dual-payload technology to deliver two distinct therapeutic agents:
• HSV-tk: Converts an orally administered antiviral drug (valaciclovir) into a toxic agent that directly kills proliferating tumour cells.
• IL-12: Acts as an immune-stimulating cytokine that turns the tumour into an in-situ vaccine, training the body's immune system to attack the cancer and prevent recurrence.
We have had many false dawns in GBM trials but we are very excited by the results so far with TGX-007.

Part 1 of 2 and this is a trial story we want to follow through.

Enjoy!!!